Clinical Trial Update: A Study of Rilzabrutinib in Adult Patients With Immune Thrombocytopenia (ITP) [Phase 2]

View source ↗

Summary

Phase 2 study of rilzabrutinib in adults with immune thrombocytopenia has completed, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immune Thrombocytopenia

Drugs mentioned

• Rilzabrutinib (rilzabrutinib)

Snippet

Sponsor: Principia Biopharma, a Sanofi Company | Conditions: Immune Thrombocytopenia | Phase 2 | Status: COMPLETED | Results posted: 2025-11-14